Evidence map›Paper›PMID 11498788›Full record

ArticleOncogene2001

Dynamic in vivo interactions among Myc network members.

X Yin, M F Landay, W Han, E S Levitan, S C Watkins, R M Levenson, D L Farkas, E V Prochownik

RetractedAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Burkitt's and Burkitt-like lymphoma.Current treatment options in oncology · 2002
    Review
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

X YinSection of Hematology/Oncology, Department of Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, PA 15213, USA.
M F Landay
W Han
E S Levitan
S C Watkins
R M Levenson
D L Farkas
E V Prochownik
Children's Hospital of Pittsburgh · USUniversity of Pittsburgh Medical Center · USUPMC Hillman Cancer Center · USCarnegie Mellon University · USUniversity of Pittsburgh · US

Funding

C-, N-, AND L-MYC EFFECTS ON HEMATOPOIETIC CELLSR01CA078259 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PROCHOWNIK, EDWARD VICTOR · 1999 to 2009
$2.0M
MOLECULAR BIOLOGY OF HEMATOPOIETIC DIFFERENTIATIONR01HL033741 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PROCHOWNIK, EDWARD V · 1985 to 2000
$341k
NCI NIH HHS CA 78259NHLBI NIH HHS HL33741
6 · The paper itself

Abstract

Members of the Myc oncoprotein network (c-Myc, Max, and Mad) play important roles in proliferation, differentiation, and apoptosis. We expressed chimeric green fluorescent protein (GFP) fusions of c-Myc, Max, and three Mad proteins in fibroblasts. Individually, c-Myc and Mad proteins localized in subnuclear speckles, whereas Max assumed a homogeneous nuclear pattern. These distributions were co-dominant and dynamic, however, as each protein assumed the pattern of its heterodimeric partner when the latter was co-expressed at a higher level. Deletion mapping of two Mad members, Mad1 and Mxi1, demonstrated that the domains responsible for nuclear localization and speckling are separable. A non-speckling Mxi1 mutant was also less effective as a transcriptional repressor than wild-type Mxi1. c-Myc nuclear speckles were distinct from SC-35 domains involved in mRNA processing. However, in the presence of co-expressed Max, c-Myc, but not Mad, co-localized to a subset of SC-35 loci. These results show that Myc network proteins comprise dynamic subnuclear structures and behave co-dominantly when co-expressed with their normal heterodimerization partners. In addition, c-Myc-Max heterodimers, but not Max-Mad heterodimers, localize to foci actively engaged in pre-mRNA transcription/processing. These findings suggest novel means by which Myc network members promote transcriptional activation or repression.

Indexed as

I-kappa B Proteins3T3 CellsAnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBasic Helix-Loop-Helix ProteinsBasic-Leucine Zipper Transcription FactorsBlotting, WesternCell CompartmentationCell Cycle ProteinsCell LineCell NucleusCOS CellsDNA-Binding ProteinsGreen Fluorescent ProteinsLuminescent ProteinsMiceBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBasic Helix-Loop-Helix ProteinsBasic-Leucine Zipper Transcription FactorsCell Cycle ProteinsDNA-Binding ProteinsGreen Fluorescent ProteinsI-kappa B ProteinsLuminescent ProteinsMad1l1 protein, mouseMax protein, mouseMax protein, ratMXI1 protein, humanMxi1 protein, mouseMxi1 protein, ratMyc associated factor XNF-KappaB Inhibitor alphaNFKBIA protein, humanNfkbia protein, mouseNfkbia protein, ratNuclear ProteinsPhosphoproteinsProto-Oncogene Proteins c-mycRecombinant Fusion ProteinsRepressor ProteinsTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID11498788
OpenAlexW2331264478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.